---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-067614"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-05-28T21:09:53+00:00"
generated_at: "2026-05-28T21:14:48.874756+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics raises ~$5M in registered direct offering at $0.5855/share; warrants repriced

## Summary
- Gross proceeds of ~$5.0M from sale of 8,539,709 shares at $0.5855 per share.
- Warrant amendment reduces exercise price of 15,488,570 warrants from $1.78 to $0.5855.
- Offering expected to close May 29, 2026; net proceeds for working capital and general corporate purposes.
- Purchaser GMS Ventures is affiliated with directors Yezan Haddadin and Faisal G. Sukhtian.

## SEC filing metadata
- accession: 0001104659-26-067614
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-05-28T21:09:53+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926067614/0001104659-26-067614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926067614/tm2615925d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-067614
- JSON: https://secwatch.observer/filing/0001104659-26-067614.json
- Plain text: https://secwatch.observer/filing/0001104659-26-067614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.